BioSpace News Archive

BioCapital

Avalo Completes Divestiture of AVTX-800 Series

Avalo Therapeutics, Inc., announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801, AVTX-802 and AVTX-803 to AUG Therapeutics, LLC.

October 31, 2023
·
4 min read
Pharm Country

Galera Announces Receipt of Type A Meeting Minutes and Strategic Update

Galera Therapeutics, Inc. announced that it has received official meeting minutes from the Type A meeting with the United States Food and Drug Administration held September 28, 2023 in which the FDA reiterated the need for an additional Phase 3 trial of avasopasem manganese for radiotherapy-induced SOM.

October 31, 2023
·
7 min read
Pharm Country

Axsome Therapeutics to Present at Upcoming November 2023 Investor Conferences

Axsome Therapeutics, Inc. announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences in early November.

October 31, 2023
·
4 min read
BioMidwest

NAYZILAM® (midazolam) Results Published in ‘Epilepsy & Behavior’ Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB, a global biopharmaceutical company, announced that Epilepsy & Behavior published a post hoc analysis from the Phase 3 open-label extension study of NAYZILAM.

October 31, 2023
·
15 min read
Biotech Beach

Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2023, raised 2023 net sales guidance for INGREZZA, and announced an Analyst Day to be held in New York City on December 5th.

October 31, 2023
·
14 min read
Business

Nautilus Biotechnology Reports Third Quarter 2023 Financial Results

Nautilus Biotechnology, Inc. today reported financial results for the third quarter ended September 30, 2023.

October 31, 2023
·
8 min read
Genetown

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

Centessa Pharmaceuticals plc today announced the dosing of the first subject in its registrational PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors.

October 31, 2023
·
6 min read
Genetown

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

X4 Pharmaceuticals today announced that the United States Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for once-daily, oral mavorixafor.

October 31, 2023
·
6 min read
Meihua International Medical Technologies Co., Ltd. Establishes A Subsidiary Dedicated to Introducing International Patented Pharmaceuticals and Medical Device Technologies to China and Hainan Free Trade Port Boao Hope City

Meihua International Medical Technologies Co., Ltd. announced the establishment of a subsidiary, Hainan Ruiying Technology Co., Ltd., in the Hainan Free Trade Port Boao Hope City in Qionghai City, Hainan Province.

October 31, 2023
·
6 min read
Biotech Bay

Aqtual Raises $16 Million in Series A Funds

Aqtual, Inc., a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology, has raised $16 million in Series A financing, co-led by Genoa Ventures, Manta Ray Ventures, and Yu Galaxy.

October 31, 2023
·
3 min read